Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
THE BEST BLACK FRIDAY DEAL YET (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Airbnb has a plan to fix cleaning fees
See how to make money instead of spending it on Black Friday with this offer (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Railway workers in Austria to strike Monday in pay standoff
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
THE BEST BLACK FRIDAY DEAL YET (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Airbnb has a plan to fix cleaning fees
See how to make money instead of spending it on Black Friday with this offer (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Railway workers in Austria to strike Monday in pay standoff
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
THE BEST BLACK FRIDAY DEAL YET (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Airbnb has a plan to fix cleaning fees
See how to make money instead of spending it on Black Friday with this offer (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Railway workers in Austria to strike Monday in pay standoff
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
THE BEST BLACK FRIDAY DEAL YET (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Airbnb has a plan to fix cleaning fees
See how to make money instead of spending it on Black Friday with this offer (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Railway workers in Austria to strike Monday in pay standoff

AC Immune - ACIU Stock Forecast, Price & News

$2.76
+0.19 (+7.39%)
(As of 11/25/2022 04:00 PM ET)
Add
Compare
Today's Range
$2.52
$2.78
50-Day Range
$2.40
$3.29
52-Week Range
$2.06
$5.41
Volume
42,116 shs
Average Volume
71,691 shs
Market Capitalization
$230.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00

AC Immune MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
371.0% Upside
$13.00 Price Target
Short Interest
Healthy
1.04% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.66mentions of AC Immune in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.87) to ($0.01) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.05 out of 5 stars

Medical Sector

612th out of 1,044 stocks

Pharmaceutical Preparations Industry

293rd out of 510 stocks

ACIU stock logo

About AC Immune (NASDAQ:ACIU) Stock

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Receive ACIU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AC Immune and its competitors with MarketBeat's FREE daily newsletter.

ACIU Stock News Headlines

Is Ardelyx is A Buy After Slip in Early 2022 (ACIU)
Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them
Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?
See More Headlines
Receive ACIU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AC Immune and its competitors with MarketBeat's FREE daily newsletter.

ACIU Company Calendar

Last Earnings
10/28/2022
Today
11/27/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/28/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACIU
Employees
137
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$13.00
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+371.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-79,860,000.00
Pretax Margin
-1,910.63%

Debt

Sales & Book Value

Annual Sales
$16.46 million
Book Value
$2.35 per share

Miscellaneous

Free Float
N/A
Market Cap
$230.60 million
Optionable
Not Optionable
Beta
0.53

Key Executives

  • Dr. Andrea Pfeifer Ph.D. (Age 65)
    Co-Founder, CEO & Director
    Comp: $1.2M
  • Mr. Piergiorgio Donati (Age 51)
    Chief Technical Operations Officer
  • Dr. Marie Kosco-Vilbois (Age 64)
    Chief Scientific Officer
  • Mr. Jean-Fabien Monin (Age 51)
    Chief Admin. Officer
  • Prof. Johannes Rolf Streffer M.D. (Age 53)
    Chief Medical Officer
  • Mr. Christopher Roberts
    Interim CFO & VP of Fin.
  • Mr. Joshua Drumm Ph.D.
    Head of Investor Relations
  • Mr. Alexandre Caratsch (Age 56)
    Gen. Counsel
  • Judith Moore
    Global Head of Communications
  • Mr. Julian Snow
    VP of U.S. Fin. & Corp. Devel.













ACIU Stock - Frequently Asked Questions

Should I buy or sell AC Immune stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACIU shares.
View ACIU analyst ratings
or view top-rated stocks.

What is AC Immune's stock price forecast for 2023?

2 Wall Street analysts have issued 12-month price targets for AC Immune's shares. Their ACIU share price forecasts range from $10.00 to $16.00. On average, they anticipate the company's share price to reach $13.00 in the next twelve months. This suggests a possible upside of 371.0% from the stock's current price.
View analysts price targets for ACIU
or view top-rated stocks among Wall Street analysts.

How have ACIU shares performed in 2022?

AC Immune's stock was trading at $4.95 at the beginning of 2022. Since then, ACIU stock has decreased by 44.2% and is now trading at $2.76.
View the best growth stocks for 2022 here
.

When is AC Immune's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023.
View our ACIU earnings forecast
.

How were AC Immune's earnings last quarter?

AC Immune SA (NASDAQ:ACIU) posted its quarterly earnings results on Friday, October, 28th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.07. The company earned $4.07 million during the quarter, compared to analyst estimates of $0.73 million.

What is Andrea Pfeifer's approval rating as AC Immune's CEO?

3 employees have rated AC Immune Chief Executive Officer Andrea Pfeifer on Glassdoor.com. Andrea Pfeifer has an approval rating of 35% among the company's employees. This puts Andrea Pfeifer in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of AC Immune own?
When did AC Immune IPO?

(ACIU) raised $55 million in an initial public offering (IPO) on Friday, September 23rd 2016. The company issued 4,600,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

What is AC Immune's stock symbol?

AC Immune trades on the NASDAQ under the ticker symbol "ACIU."

Who are AC Immune's major shareholders?

AC Immune's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.52%), BlackRock Inc. (0.44%), Kingsbury Capital Investment Advisors LLC (0.03%), Balyasny Asset Management LLC (0.03%) and Group One Trading L.P. (0.00%).

How do I buy shares of AC Immune?

Shares of ACIU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AC Immune's stock price today?

One share of ACIU stock can currently be purchased for approximately $2.76.

How much money does AC Immune make?

AC Immune (NASDAQ:ACIU) has a market capitalization of $230.60 million and generates $16.46 million in revenue each year. The company earns $-79,860,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis.

How many employees does AC Immune have?

The company employs 137 workers across the globe.

How can I contact AC Immune?

AC Immune's mailing address is EPFL Innovation Park Building B, Lausanne V8, 1015. The official website for the company is www.acimmune.com. The company can be reached via phone at (121) 693-9121, via email at ir@acimmune.com, or via fax at 41-21-345-9120.

This page (NASDAQ:ACIU) was last updated on 11/27/2022 by MarketBeat.com Staff